Treatment of vulvo-vaginal atrophy with hyaluronate-based gel: a randomized controlled study

Minerva Obstet Gynecol. 2022 Dec;74(6):480-488. doi: 10.23736/S2724-606X.21.04841-7. Epub 2021 Jun 7.

Abstract

Background: The study aimed to assess the performance and safety of single-use applicators prefilled with hyaluronic acid (HA)-based vaginal gel (Hyalo Gyn) for the treatment of vulvovaginal atrophy (VVA)-related signs and symptoms in postmenopausal women.

Methods: Eighty women were randomized, 46 to Hyalo Gyn gel and 34 to a standard treatment (water-based lubricant). Outcome data collected included: the proportion of subjects having a reduction ≥1 point in the Verbal Rating Scale (VRS) Dryness Score, VRS Global Score, vaginal pH, Vaginal Health Index, Female Sexual Function Index, Female Sexual Distress Scale-Revised, patients' global assessment, tolerability, and safety.

Results: Significant improvements were observed for all the assessed endpoints in both treatment groups. The perception of any improvement on the VRS Dryness Score was not statistically different between the treatment groups. A sensitivity analysis on the absolute change in VRS Dryness Score showed a statistically significant difference in favor of the Hyalo Gyn group at 3 months.

Conclusions: A 3-month treatment with Hyalo Gyn gel is effective, safe, and well tolerated for VVA-related symptoms in postmenopausal women.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Atrophy / drug therapy
  • Female
  • Humans
  • Postmenopause*
  • Treatment Outcome
  • Vaginal Diseases* / drug therapy
  • Vulva / pathology